In a world saturated with policy slogans and risk frameworks, what’s often missing is structural insight:
How do systems actually produce ethical outcomes, or fail to?
Not performative safety. Not reputational cover.
In modern regulatory systems—especially in pharma, biotech, and AI ethics—compliance is often mistaken for protection.
Procedures are followed.
Forms are complete.
Audits are passed.
And yet, harm continues, truth is missed,
AI is beginning to outperform traditional pipelines in identifying drug candidates.
Not hypothetically: measurably.
Modern generative platforms can now design molecules that bind their targets with high affinity, minimize off-target effects, and predict
